Boston Scientific

BSX Health Care Market cap $65.3B as of Sep 14, 2026 16:00 ET S&P 500

Q2 FY26 Apr 1 – Jun 30, 2026 reported Aug 3, 2026

Revenue$5.44B +8% year over year

Gross profit$3.85B 71% margin

Operating profit$1.18B 22% margin

Net profit$0.91B 17% margin

The numbers behind the diagram

All figures in billions of U.S. dollars, for Q2 FY26 (period ends Jun 30, 2026).
Item	Value	Share of revenue	Year over year
Revenue	5.44	100%	+8%
Cardiology therapies	1.33	24%
Electrophysiology	0.92	17%	+9%
Global endoscopy	0.79	15%	+8%
Urology & pelvic health	0.68	13%	+1%
Cardiac rhythm management	0.59	11%	−1%
Watchman	0.51	9%	+4%
Neuromodulation	0.34	6%	+13%
Interventional oncology	0.28	5%
Cost of revenue	−1.59	29%
Gross profit	3.85	71% margin	+3pp
SG&A	−1.80	33%	−1pp
Other	−0.87	16%	+0pp
Operating profit	1.18	22% margin	+5pp
Interest & other costs	−0.12
Tax	−0.16
Net profit	0.91	17% margin	+1pp

Figures are rounded to the precision shown, so a column can differ slightly from its own total.

Filing on EDGAR This quarter on its own page

All figures in billions of U.S. dollars, for Q1 FY26 (period ends Mar 31, 2026).
Item	Value	Share of revenue	Year over year
Revenue	5.20	100%	+12%
Cardiology therapies	1.24	24%
Electrophysiology	0.91	17%	+24%
Global endoscopy	0.74	14%	+9%
Urology & pelvic health	0.65	13%	+2%
Cardiac rhythm management	0.58	11%	+0%
Watchman	0.51	10%	+19%
Neuromodulation	0.32	6%	+17%
Interventional oncology	0.27	5%
Cost of revenue	−1.59	31%
Gross profit	3.61	69% margin	+1pp
SG&A	−1.78	34%	+0pp
Other	−0.73	14%	+0pp
Operating profit	1.10	21% margin	+1pp
Tax benefit and other	0.24
Net profit	1.34	26% margin	+11pp

Figures are rounded to the precision shown, so a column can differ slightly from its own total.

Filing on EDGAR This quarter on its own page

All figures in billions of U.S. dollars, for Q4 FY25 (period ends Dec 31, 2025).
Item	Value	Share of revenue	Year over year
Revenue	5.3	100%	+16%
US	3.4	64%	+17%
Non US	1.9	36%	+14%
Cost of revenue	−1.6	30%
Gross profit	3.7	70% margin	+2pp
SG&A	−1.8	35%	−1pp
Other	−1.0	19%	+0pp
Operating profit	0.8	16% margin	+1pp
Interest & other costs	−0.1
Tax	−<0.1
Net profit	0.7	13% margin	+0pp

Figures are rounded to the precision shown, so a column can differ slightly from its own total.

Filing on EDGAR This quarter on its own page

All figures in billions of U.S. dollars, for Q3 FY25 (period ends Sep 30, 2025).
Item	Value	Share of revenue	Year over year
Revenue	5.07	100%	+20%
Electrophysiology	0.87	17%	+64%
Global endoscopy	0.75	15%	+10%
Peripheral interventions	0.70	14%	+17%
Interventional cardiology	0.69	14%	+4%
Urology & pelvic health	0.68	13%	+28%
Cardiac rhythm management	0.58	11%	+3%
Watchman	0.51	10%	+35%
Neuromodulation	0.29	6%	+9%
Cost of revenue	−1.52	30%
Gross profit	3.54	70% margin	+1pp
SG&A	−1.74	34%	−3pp
Other	−0.75	15%	+0pp
Operating profit	1.05	21% margin	+3pp
Interest & other costs	−0.11
Tax	−0.18
Net profit	0.76	15% margin	+4pp

Figures are rounded to the precision shown, so a column can differ slightly from its own total.

Filing on EDGAR This quarter on its own page

All figures in billions of U.S. dollars, for Q2 FY25 (period ends Jun 30, 2025).
Item	Value	Share of revenue	Year over year
Revenue	5.06	100%	+23%
Electrophysiology	0.84	17%	+96%
Global endoscopy	0.74	14%	+9%
Interventional cardiology	0.73	14%	+10%
Peripheral interventions	0.70	14%	+18%
Urology & pelvic health	0.68	13%	+29%
Cardiac rhythm management	0.59	12%	+2%
Watchman	0.49	10%	+28%
Neuromodulation	0.30	6%	+7%
Cost of revenue	−1.64	32%
Gross profit	3.42	68% margin	−2pp
SG&A	−1.72	34%	−1pp
Other	−0.89	17%	+0pp
Operating profit	0.82	16% margin	+4pp
Other income, net	0.12
Tax	−0.15
Net profit	0.80	16% margin	+8pp

Figures are rounded to the precision shown, so a column can differ slightly from its own total.

Filing on EDGAR This quarter on its own page

All figures in billions of U.S. dollars, for Q1 FY25 (period ends Mar 31, 2025).
Item	Value	Share of revenue	Year over year
Revenue	4.66	100%	+21%
Electrophysiology	0.73	16%	+143%
Interventional cardiology	0.70	15%	+7%
Global endoscopy	0.67	14%	+5%
Peripheral interventions	0.66	14%	+14%
Urology & pelvic health	0.63	14%	+23%
Cardiac rhythm management	0.58	12%	+1%
Watchman	0.43	9%	+24%
Neuromodulation	0.27	6%	+6%
Cost of revenue	−1.45	31%
Gross profit	3.21	69% margin	+0pp
SG&A	−1.60	34%	−1pp
Other	−0.69	15%	+0pp
Operating profit	0.92	20% margin	+2pp
Interest & other costs	−0.12
Tax	−0.13
Net profit	0.67	14% margin	+2pp

Figures are rounded to the precision shown, so a column can differ slightly from its own total.

Filing on EDGAR This quarter on its own page

Financial health

The balance sheet, the quarter's capital flow, the debt schedule and the capital structure of the quarter shown above.

Every set of results we hold, newest first. Open one on its own page.

Quarter	Period	Reported	Revenue	Year over year	Operating margin	Net profit	Net margin
Q2 FY26 Apr 1 – Jun 30, 2026 reported Aug 3, 2026 Operating margin 22% Net profit $0.91B	Apr 1 – Jun 30, 2026	Aug 3, 2026	$5.44B	+8%	22%	$0.91B	17%
Q1 FY26 Jan 1 – Mar 31, 2026 reported May 1, 2026 Operating margin 21% Net profit $1.34B	Jan 1 – Mar 31, 2026	May 1, 2026	$5.20B	+12%	21%	$1.34B	26%
Q4 FY25 Oct 1 – Dec 31, 2025 reported Feb 17, 2026 Operating margin 16% Net profit $0.67B	Oct 1 – Dec 31, 2025	Feb 17, 2026	$5.29B	+16%	16%	$0.67B	13%
Q3 FY25 Jul 1 – Sep 30, 2025 reported Nov 3, 2025 Operating margin 21% Net profit $0.76B	Jul 1 – Sep 30, 2025	Nov 3, 2025	$5.07B	+20%	21%	$0.76B	15%
Q2 FY25 Apr 1 – Jun 30, 2025 reported Aug 1, 2025 Operating margin 16% Net profit $0.80B	Apr 1 – Jun 30, 2025	Aug 1, 2025	$5.06B	+23%	16%	$0.80B	16%
Q1 FY25 Jan 1 – Mar 31, 2025 reported May 1, 2025 Operating margin 20% Net profit $0.67B	Jan 1 – Mar 31, 2025	May 1, 2025	$4.66B	+21%	20%	$0.67B	14%